FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:2539-2549 December 15, 2005 Number 24 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Bermas, B. L. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The effects of estrogen-containing contraceptives on disease activity in women with systemic lupus erythematosus have not been determined.

Methods We conducted a single-blind clinical trial involving 162 women with systemic lupus erythematosus who were randomly assigned to combined oral contraceptives, a progestin-only pill, or a copper intrauterine device (IUD). Disease activity was assessed at 0, 1, 2, 3, 6, 9, and 12 months according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). The primary outcome was global disease activity, which we estimated by measuring the area under the SLEDAI curve. Secondary outcomes included the maximum SLEDAI score, change in SLEDAI score, incidence of lupus flares, median time to first flare, systemic lupus erythematosus treatment, and adverse events. The results were analyzed by the intention-to-treat method.

Results At baseline, all demographic features and disease characteristics were similar in the three groups. The mean (±SD) SLEDAI score was 6.1±5.6 in the group assigned to combined oral contraceptives, 6.4±4.6 in the group assigned to the progestin-only pill, and 5.0±5.3 in the group assigned to the IUD (54 patients in each group) (P=0.36). Disease activity remained mild and stable in all groups throughout the trial. There were no significant differences among the groups during the trial in global or maximum disease activity, incidence or probability of flares, or medication use. The median time to the first flare was three months in all groups. Thromboses occurred in four patients (two in each of the two groups receiving hormones), and severe infections were more frequent in the IUD group. One patient receiving combined oral contraceptives died from amoxicillin-related severe neutropenia.

Conclusions Global disease activity, maximum SLEDAI score, incidence of flares, time to first flare, and incidence of adverse events were similar among women with systemic lupus erythematosus, irrespective of the type of contraceptive they were using.

Source Information

From the Departments of Immunology and Rheumatology (J.S.-G., A.G.U., M.M.-P., P.L.-R.), and Reproductive Biology (L.J.-S., M.-C.C.), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; and the Department of Reproductive Health and Research, World Health Organization, Geneva (A.H.S.).

Address reprint requests to Dr. Sánchez-Guerrero at the Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Mexico City 14000, Mexico, or at jsanchez{at}innsz.mx.

Full Text of this Article

Related Letters:

Oral Contraceptives in Women with Systemic Lupus Erythematosus
Schwarz E. B., Lohr P. A., Sánchez-Guerrero J., Jiménez-Santana L., Cravioto M.-d.-C.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:1203-1204, Mar 16, 2006. Correspondence

This article has been cited by other articles:

• Browne, H., Manipalviratn, S., Armstrong, A. (2008). Using an Intrauterine Device in Immunocompromised Women. Obstet Gynecol 112: 667-669 [Abstract] [Full Text]  
• Yuen, S. Y., Pope, J. E. (2008). Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials. Rheumatology (Oxford) 47: 1367-1372 [Abstract] [Full Text]  
• Petri, M, Buyon, J. (2008). Editorial: Oral contraceptives in systemic lupus erythematosus: the case for (and against). Lupus 17: 708-710  
• Petri, M (2008). Sex hormones and systemic lupus erythematosus. Lupus 17: 412-415 [Abstract]  
• Bertsias, G, Ioannidis, J P A, Boletis, J, Bombardieri, S, Cervera, R, Dostal, C, Font, J, Gilboe, I M, Houssiau, F, Huizinga, T, Isenberg, D, Kallenberg, C G M, Khamashta, M, Piette, J C, Schneider, M, Smolen, J, Sturfelt, G, Tincani, A, van Vollenhoven, R, Gordon, C, Boumpas, D T (2008). EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67: 195-205 [Abstract] [Full Text]  
• Tincani, A., Nuzzo, M., Lojacono, A., Cattalini, M., Meini, A. (2007). Review: Contraception in adolescents with systemic lupus erythematosus. Lupus 16: 600-605 [Abstract]  
• Straub, R. H. (2007). The Complex Role of Estrogens in Inflammation. Endocr. Rev. 28: 521-574 [Abstract] [Full Text]  
• D'Cruz, D. P (2006). Systemic lupus erythematosus.. BMJ 332: 890-894 [Full Text]  
• Schwarz, E. B., Lohr, P. A., Sanchez-Guerrero, J., Jimenez-Santana, L., Cravioto, M.-d.-C. (2006). Oral contraceptives in women with systemic lupus erythematosus.. NEJM 354: 1203-1204 [Full Text]  
• (2006). Which Contraceptives for Women with Lupus?. JWatch Women's Health 2006: 4-4 [Full Text]  
• Keram, E. A. (2006). Will medical ethics be a casualty of the war on terror?. J Am Acad Psychiatry Law 34: 6-8 [Full Text]  
• Bermas, B. L. (2005). Oral Contraceptives in Systemic Lupus Erythematosus -- A Tough Pill to Swallow?. NEJM 353: 2602-2604 [Full Text]